

More than 5,000 Covid Vaccine Deaths in America, 25,359 "Serious Injuries" and Almost 300,000 Reported "Adverse Events"

Lates VAERS data released showed 294,801 reports of adverse events following COVID vaccines, including 5,165 deaths and 25,359 serious injuries between Dec. 14, 2020 and May 28, 2021.

By Megan Redshaw

Global Research, June 05, 2021

Children's Health Defense


Region: <u>USA</u>
Theme: Science and Medicine

This week's number of reported deaths among all age groups following COVID vaccines passed the 5,000 mark, up 759 from last week, according to data released today by the Centers for Disease Control and Prevention (CDC). The data comes directly from reports submitted to the <u>Vaccine Adverse Event Reporting System</u> (VAERS).

<u>VAERS</u> is the primary government-funded system for reporting adverse vaccine reactions in the U.S. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Every Friday, VAERS makes public all vaccine injury reports received as of a specified date, usually about a week prior to the release date. Today's data show that between Dec. 14, 2020 and May 28, a total of 294,801 total adverse events were reported to VAERS, including 5,165 deaths — an increase of 759 over the previous week. There were 25,359 serious injuries reported, up 3,822 compared with last week.

Among 12- to 17-year-olds, there were <u>40 reports</u> of heart inflammation and <u>16 cases</u> of blood clotting disorders.



Search Results

From the 5/28/2021 release of VAERS data:

Found 294,801 cases where Vaccine is COVID19

Event Outcome	*+	
	Court	Percent
Seath	8,166	1.70%
Permanent Disability	1.864	1.56%
Office Visit	Stain	17,34%
Emergency Room	44	0.01%
Emergency Docton/Room	34.876	13.28%
Hospitalizad	17.579	5.98%
Hospitalized, Prolonged	40	5.56% 5.56% 0.07% 38.17%
Becavered	112,364	28.17%
Birth Defect	187	0.081
Life Threatening	5.216	1.8%
Not Serious	115,476	39.17%
TOTAL	1383.894	1118.045

In the U.S., <u>292.1 million</u> COVID vaccine doses had been administered as of May 28. This <u>includes</u> 123 million doses of <u>Moderna's</u> vaccine, 158 million doses of <u>Pfizer</u> and 11 million doses of the <u>Johnson & Johnson</u> (J&J) COVID vaccine.

Of the 5,165 deaths reported as of May 28, <u>24% occurred</u> within 48 hours of vaccination, <u>16% occurred</u> within 24 hours and <u>38% occurred</u> in people who became ill <u>within 48 hours</u> of being vaccinated.

This week's data for 12- to 17-year-olds show:

- 4,740 total adverse events, including 117 rated as serious and four reported deaths among 12 to 17-year-olds. The youngest deaths reported include two 15-year-olds (VAERS I.D. 1187918 and 1242573), a 16-year-old (VAERS I.D. 1225942) and one 17-year-old (VAERS I.D. 1199455). There were other reported deaths in children under 17 that could not be confirmed or contained obvious errors.
- <u>635 reports</u> of anaphylaxis among 12- to17-year-olds with 97% of cases attributed to <u>Pfizer's vaccine</u>, 2% to <u>Moderna</u> and 0.31% (or two cases) to <u>J&J</u>.
- 40 reports of myocarditis and pericarditis (heart inflammation) all attributed to Pfizer's COVID vaccine.
- 16 reports of blood clotting disorders, all attributed to Pfizer.

This week's total VAERS data, from Dec. 14, 2020, to May 28, 2021, for all age groups show:

- 17% of deaths were related to cardiac disorders.
- 52% of those who died were male, 45% were female and the remaining death

reports did not include gender of the deceased.

- The <u>average age</u> of death was 74.4.
- As of May 28, 1,831 pregnant women reported adverse events related to COVID vaccines, including 596 reports of miscarriage or premature birth.
- Of the <u>2,876 cases of Bell's Palsy reported</u>, 52% were reported after <u>Pfizer</u> vaccinations, 41% following vaccination with the Moderna vaccine and 253 cases, or 9%, of Bell's Palsy cases were reported in conjunction with J&J.
- 280 reports of Guillain-Barré Syndrome with 46% of cases attributed to Pfizer, 40% to Moderna and 20% to J&J.
- <u>83,684 reports of anaphylaxis</u> with 40% of cases attributed to <u>Pfizer's vaccine</u>, 51% to <u>Moderna</u>and 9% to <u>J&J</u>.
- <u>5,159 reports</u> of blood clotting disorders. Of those, <u>2,213 reports</u> were attributed to Pfizer, <u>1,617 reports</u> to Moderna and <u>1,289 reports</u> to J&J.

Seven cases of heart inflammation reported in teen boys, new study shows

On June 4, <u>The Defender reported</u> seven boys between the ages of 14 and 19 in the U.S. <u>reportedly developed</u> chest pain and heart inflammation within four days of receiving a second dose of the Pfizer vaccine, according to a <u>study</u> published today in Pediatrics.

Heart imaging tests detected a rare type of heart muscle inflammation called myocarditis and pericarditis. None of the teens were critically ill but all were hospitalized.

Only one of the seven boys in the Pediatrics report displayed evidence of a possible previous COVID infection, and doctors determined none of them had a rare inflammatory condition linked with COVID or pre-existing conditions. It is possible myocarditis or pericarditis may be an additional rare adverse event related to systemic reactogenicity, but currently no causal association has been established between this vaccine and myopericarditis, the authors concluded.

A search in VAERS revealed <u>628 cases</u> of myocarditis and pericarditis, among all age groups reported in the U.S following COVID vaccination between Dec.14, 2020 and May 28. Of the 628 cases reported, <u>392 cases</u> were attributed to Pfizer, <u>206 cases</u> to Moderna and <u>27 cases</u> to J&J's COVID vaccine.

Of the 628 total cases of heart inflammation, <u>40 cases</u> occurred in children ages 12 to 17, all attributed to Pfizer's COVID vaccine.

CHD Calls on FDA to Take COVID Vaccines Off the Market - Submit a Comment

Israeli health officials find probable link between Pfizer vaccine and heart inflammation

As <u>The Defender reported</u> June 2, Israeli health officials found a probable link between Pfizer's COVID vaccine — which the country has relied on almost exclusively in its vaccination drive — and dozens of cases of heart inflammation in young men following the second dose.

A study by Israeli health officials identified 275 cases of myocarditis in Israel between December 2020 and May 2021, including 148 cases that occurred within a month after vaccination. Of those 148 cases, 27 occurred after the first dose and 121 after the second dose. About half of the cases involved people with previous medical conditions.

Many of the <u>cases were reported</u> among men 16 to 30 years old, and most often in 16- to 19-year-olds. Most of the patients were discharged from the hospital in less than four days, and 95% of the cases were considered mild.

New research shows COVID vaccine spike protein travels from injection site

On June 3, <u>The Defender reported</u> on research obtained by a group of scientists showing the COVID vaccine spike protein can travel from the injection site and accumulate in organs and tissues including the spleen, bone marrow, liver, adrenal glands and in "quite high concentrations" in the ovaries.

COVID vaccine <u>researchers had previously assumed</u> mRNA COVID vaccines would behave like traditional vaccines. The vaccine's spike protein — responsible for infection and its most severe symptoms — would remain mostly in the injection site at the shoulder muscle or local lymph nodes.

The new research for the first time provided scientists the opportunity to see where messenger RNA [mRNA] vaccines go after vaccination."

Woman who almost died after J&J vaccine stuck with \$1 million in medical bills

As <u>The Defender reported</u> June 2, a 38-year-old woman who suffered multiple organ failure from J&J's COVID vaccine said victims should be compensated by the government for taking the risk.

Kendra Lippy was diagnosed with <u>severe blood clots</u> resulting in 33 days of hospitalization. She suffered organ failure, and was left without most of her small intestine — and with crippling medical bills.

Lippy's case was one of the six that led federal agencies to temporarily <u>pause the J&J shot in mid-April</u>.

Because the government shielded vaccine makers from liability, Lippy can't sue J&J. She also doesn't have a legitimate legal route to sue the government. The only current option for people who have suffered COVID vaccine injuries is the <u>Countermeasures Injury Compensation Program</u>(CICP), which turns down most applicants. Fewer than one in 10 people receive compensation after applying.

According to data from CICP, more than 701 claim filings since 2010 have been received from individuals requesting compensation for injuries. Of the 701 claims, only 29 claims were compensated totaling \$6 million. Another 452 claims were deemed ineligible. There are 210 cases pending. As of May 26, CICP had received 152 claims involving COVID vaccines, and 293 involving other treatments.

Moderna applies for full FDA approval of its COVID vaccine

On June 1, <u>CNBC reported</u> Moderna asked the U.S. Food and Drug Administration (FDA) for full U.S. approval of its COVID vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers. The mRNA vaccine is currently only approved under an Emergency Use Authorization, which was granted by the FDA in December. The FDA approval process is likely to take months.

On May 10, the FDA amended the <u>Emergency Use Authorization</u> for Pfizer's COVID vaccine to include 12- to 15-year-olds. On May 7, the vaccine maker also <u>applied for full approval</u> of its vaccine. Currently, only Pfizer's vaccine is approved for emergency use in the 12 to 15 age group.

88 days and counting, CDC ignores The Defender's inquiries

According to the <u>CDC website</u>, "the CDC follows up on any report of death to request additional information and learn more about what occurred and to determine whether the death was a result of the vaccine or unrelated."

On March 8, <u>The Defender</u> contacted the CDC with a <u>written list of questions</u> about reported deaths and injuries related to COVID vaccines. After repeated attempts, by phone and email, to obtain a response to our questions, a health communications specialist from the CDC's Vaccine Task Force contacted us on March 29 — three weeks after our initial inquiry.

The individual received our request for information from VAERS, but said she had never received our list of questions, even though employees we talked to several times said CDC press officers were working through the questions and confirmed the representative had received them. We provided the list of questions again along with a new deadline, but never received a response.

On May 19, a CDC employee said our questions had been reviewed and our inquiry was pending in their system, but would not provide us with a copy of the response. We were told we would be contacted by phone or email with the response.

On June 4, the CDC employee we contacted said our request was pending in the system, but nobody had responded to our inquiries. We were advised to submit our questions again, which we have done numerous times.

It has been 88 days since we sent our first email inquiring into VAERS data and reports.

Megan Redshaw is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.

The original source of this article is <u>Children's Health Defense</u> Copyright © Megan Redshaw, Children's Health Defense, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Megan Redshaw

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in

print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca